The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study

阿帕蒂尼 医学 肝细胞癌 内科学 联合疗法 胃肠病学 不利影响 肿瘤科 酪氨酸激酶抑制剂 实体瘤疗效评价标准 肝癌 无进展生存期 癌症 化疗 临床研究阶段
作者
Zeran Yang,Guang Chen,Ye Cui,Xiao Guo-wen,Ting Su,Jianan Yu,Zhiyuan Zhang,Yanjing Han,Kai-Lan Yang,Long Jin
出处
期刊:Cancer Biology & Therapy [Informa]
卷期号:20 (3): 321-327 被引量:34
标识
DOI:10.1080/15384047.2018.1529099
摘要

As a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor (VEGFR2-TKI), apatinib has a certain anti-tumor effect for a variety of solid tumors. The present study evaluates its efficacy and safety in advanced hepatocellular carcinoma (HCC). In this study, 47 patients with advanced HCC were included. TACE monotherapy group included 22 patients that responded to TACE, while the group that received TACE and apatinib included 25 patients that progressed on TACE and were able to receive apatinib off label. Median overall survival (OS) was significantly improved in the apatinib plus TACE group compared with the TACE group. Similarly, apatinib in combination with TACE significantly prolonged median progression-free survival (PFS) compared with TACE monotherapy. Furthermore, there was a significant difference between combination therapy and monotherapy in both Barcelona clinic liver cancer (BCLC) B and BCLC C group. The combination therapy had a dramatic effect on OS and PFS for patients at both BCLC B and BCLC C level. The most common clinically adverse events of apatinib plus TACE group were fatigue, weight loss, hypertension, hand-foot syndrome and anorexia, which were manageable and tolerable. The efficacy analysis showed that there was no significant association of survival benefit with age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, hypertension and hand-foot syndrome. Patients with macrovascular invasion and extrahepatic invasion showed worse survival benefits. In conclusion, apatinib combined with TACE revealed certain survival benefits for HCC patients who experienced progression following TACE, which can provide a promising strategy for HCC treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
安东路完成签到,获得积分10
刚刚
1秒前
cannon8应助外向土豆采纳,获得20
2秒前
Akim应助ZHUHONGYAO采纳,获得10
2秒前
qiu完成签到,获得积分10
2秒前
3秒前
LL完成签到,获得积分10
3秒前
亦亦发布了新的文献求助20
4秒前
小李完成签到,获得积分10
4秒前
雷自中发布了新的文献求助10
4秒前
哈哈哈发布了新的文献求助10
5秒前
所所应助扒开皮皮采纳,获得10
5秒前
6秒前
乌龙茶干完成签到,获得积分10
6秒前
受伤访波发布了新的文献求助10
7秒前
希望天下0贩的0应助cai采纳,获得10
7秒前
善学以致用应助迅速芸遥采纳,获得10
7秒前
混沌完成签到,获得积分10
7秒前
8秒前
9秒前
Wtony完成签到 ,获得积分10
9秒前
luha完成签到,获得积分10
10秒前
已而遂晴发布了新的文献求助10
11秒前
共享精神应助雷自中采纳,获得10
12秒前
13秒前
14秒前
共享精神应助yinqueshi采纳,获得10
15秒前
玲丫头完成签到,获得积分20
15秒前
15秒前
15秒前
端庄代荷完成签到 ,获得积分10
16秒前
CipherSage应助鲁彦华采纳,获得10
16秒前
椿人完成签到 ,获得积分10
16秒前
ldroc发布了新的文献求助10
16秒前
16秒前
Kail完成签到,获得积分10
17秒前
biubiufan完成签到,获得积分10
18秒前
大模型应助。。采纳,获得10
18秒前
18秒前
高分求助中
Evolution 3rd edition 1500
Lire en communiste 1000
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 700
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 700
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
2-Acetyl-1-pyrroline: an important aroma component of cooked rice 500
Ribozymes and aptamers in the RNA world, and in synthetic biology 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3181189
求助须知:如何正确求助?哪些是违规求助? 2831405
关于积分的说明 7984596
捐赠科研通 2493399
什么是DOI,文献DOI怎么找? 1330143
科研通“疑难数据库(出版商)”最低求助积分说明 635934
版权声明 602954